Stocks Health care DNA
NYSE · Health careGinkgo Bioworks Holdings, Inc. (DNA)
Ginkgo Bioworks Holdings, Inc. brought in $132.4M of revenue over the twelve months to June 30, 2026, down 37.0% from a year earlier. It posted a net loss of $290.8M. In fiscal 2025 capital spending exceeded operating cash flow by $178.7M. At June 30, 2026 it held $84.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
Watch DNA in 60 secondsWhat Ginkgo Bioworks Holdings, Inc. does
Ginkgo Bioworks Holdings, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NYSE under the ticker DNA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $170.2M | -$312.8M | -$5.64 | -$178.7M |
| 2024 | $227M | -$547M | -$10.54 | -$382.1M |
| 2023 | $251.5M | -$892.9M | -$18.37 | -$336.3M |
| 2022 | $477.7M | -$2.1B | -$50.20 | -$304.5M |
| 2021 | $313.8M | -$1.8B | -$55.82 | -$310.3M |
| 2021 | $76.7M | -$126.6M | -$4.02 | -$193.7M |
Full financial statements: income, balance sheet and cash flow
Where DNA ranks in Health care
Latest SEC filings
What Ginkgo Bioworks Holdings, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 48% to $20.2M versus the same quarter last year; diluted EPS -$0.75 versus -$1.10.
- August 5, 2026
- July 30, 2026
- July 30, 2026Passive stake changed SCHEDULE 13G/A
- June 12, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 7, 2026Quarterly report 10-Q · period to March 31, 2026Revenue fell 49% to $19.5M versus the same quarter last year; diluted EPS -$1.39 versus -$1.68.
- May 7, 2026
- April 29, 2026
- April 29, 2026Additional proxy material DEFA14A
Insider trades
What the people running Ginkgo Bioworks Holdings, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $43.7K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 15, 2026 | Henry Christian ODirector | Sold | 5,000 | $35.4K |
| August 24, 2026 | Coen Steven P.See remarks | Sold | 330 | $2.3K |
| August 21, 2026 | Coen Steven P.See remarks | Exercised options | 587 | - |
| August 21, 2026 | Coen Steven P.See remarks | Exercised options | 156 | - |
| July 17, 2026 | Coen Steven P.See remarks | Sold | 752 | $5.9K |
| July 16, 2026 | Coen Steven P.See remarks | Exercised options | 1,174 | - |
| July 16, 2026 | Coen Steven P.See remarks | Exercised options | 312 | - |
| May 22, 2026 | Coen Steven P.See remarks | Sold | 307 | $2.6K |
| May 21, 2026 | Coen Steven P.See remarks | Exercised options | 587 | - |
| May 21, 2026 | Coen Steven P.See remarks | Exercised options | 156 | - |
| April 17, 2026 | Coen Steven P.See remarks | Sold | 324 | $2.6K |
| April 16, 2026 | Coen Steven P.See remarks | Exercised options | 587 | - |
| April 16, 2026 | Coen Steven P.See remarks | Exercised options | 156 | - |
| April 13, 2026 | Coen Steven P.See remarks | Sold | 33,171 | $212.8K |
| April 10, 2026 | Coen Steven P.See remarks | Exercised options | 28,368 | - |
Who owns DNA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Reshma Shetty13D, may seek influence with 1 related filers | 10.5% | February 14, 2024 |
| Reshma P. Shetty13D, may seek influence with 1 related filers | 9.5% | February 14, 2025 |
| Cascade Investment, L.L.C.13G, passive with 1 related filers | 7.5% | November 14, 2025 |
| Viking Global Investors LP13G, passive with 6 related filers | 7.1% | May 15, 2026 |
| Austin Che13G, passive | 5% | February 14, 2025 |
| Jason Kelly13D, may seek influence | 5% | February 14, 2024 |
Largest institutional holders
Insiders
5 insiders reported holding 1,937,624 shares in total, about $20.3M at the last price.
| Holder | Shares |
|---|---|
| Shetty Reshma P.See remarks, Director, 10% owner | 774,990338,568 held indirectly |
| Canton Barry10% owner | 774,990436,422 held indirectly |
| Kelly Jason RSee remarks, Director | 316,483 |
| Coen Steven P.See remarks | 51,851 |
| Henry Christian ODirector | 19,310 |
Questions about DNA
What does Ginkgo Bioworks Holdings, Inc. do?
Ginkgo Bioworks Holdings, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NYSE under the ticker DNA.
Is Ginkgo Bioworks Holdings, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $290.8M on revenue of $132.4M.
How much revenue does Ginkgo Bioworks Holdings, Inc. make?
Over the twelve months to June 30, 2026 Ginkgo Bioworks Holdings, Inc. reported revenue of $132.4M. That is 37.0% less than a year earlier.
When did Ginkgo Bioworks Holdings, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the planned insider sale from September 17, 2026.
Similar companies
Compare DNA with
Follow DNA
Get an email when Ginkgo Bioworks Holdings, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow DNA: get an email when it filesWhere the numbers come from
Financial figures are the values Ginkgo Bioworks Holdings, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.